LGND
Ligand Pharmaceuticals Incorporated NASDAQ$227.44
Mkt Cap $4.6B
52w Low $98.89
86.6% of range
52w High $247.38
50d MA $208.74
200d MA $186.06
P/E (TTM)
35.3x
EV/EBITDA
20.4x
P/B
4.3x
Debt/Equity
0.4x
ROE
12.2%
P/FCF
74.8x
RSI (14)
—
ATR (14)
—
Beta
1.00
50d MA
$208.74
200d MA
$186.06
Avg Volume
217.6K
About
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vax…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | 1.46 | 2.02 | +38.4% | 196.17 | +0.0% | +1.1% | +3.3% | +4.1% | +6.5% | +5.1% | -1.8% | — |
| Nov 6, 2025 | AMC | 1.97 | 3.09 | +56.9% | 208.22 | -1.3% | -2.8% | +0.5% | +0.2% | -1.3% | -3.3% | -11.3% | — |
| Aug 7, 2025 | AMC | 1.54 | 1.60 | +3.9% | 146.32 | +1.3% | +2.6% | +0.5% | +4.4% | +6.6% | +5.1% | +13.4% | — |
| May 8, 2025 | AMC | 1.30 | 1.33 | +2.3% | 102.51 | -0.4% | +1.9% | +3.8% | +3.0% | +2.5% | +0.9% | +6.8% | — |
| Feb 27, 2025 | AMC | 1.37 | -1.64 | -219.7% | 115.67 | +0.3% | +5.7% | -3.0% | -0.4% | -0.2% | +0.3% | -9.1% | — |
| Nov 7, 2024 | AMC | 0.75 | -0.39 | -152.0% | 129.90 | -2.8% | -6.7% | -5.0% | -7.1% | -6.0% | -11.1% | -10.4% | — |
| Aug 6, 2024 | AMC | 1.10 | 1.40 | +27.3% | 99.04 | +1.0% | -5.8% | -2.1% | +1.1% | +0.6% | +4.0% | +4.1% | — |
| May 7, 2024 | AMC | 1.13 | 1.20 | +6.2% | 73.22 | +1.6% | +9.8% | +17.6% | +19.2% | +14.8% | +16.5% | +12.5% | — |
| Feb 27, 2024 | AMC | 0.58 | 1.05 | +81.0% | 89.20 | -1.0% | -5.4% | -11.0% | -11.8% | -14.5% | -17.0% | -18.0% | — |
| Nov 8, 2023 | AMC | 0.68 | 1.02 | +50.0% | 52.23 | +5.3% | +4.6% | +6.0% | +5.6% | +8.1% | +8.1% | +18.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | RBC Capital | Maintains | Outperform → Outperform | — | $241.79 | $243.66 | +0.8% | -3.9% | -7.0% | -5.1% | -5.9% | — |
| Apr 15 | Citigroup | Maintains | Buy → Buy | — | $232.34 | $230.43 | -0.8% | -3.1% | -3.9% | -0.2% | -0.2% | -2.4% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $213.44 | $220.00 | +3.1% | +8.9% | +5.5% | +4.6% | +8.6% | +8.6% |
| Mar 24 | Citigroup | Maintains | Buy → Buy | — | $200.36 | $200.88 | +0.3% | +0.6% | +2.1% | +1.7% | -2.4% | -3.9% |
| Feb 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $196.17 | $196.17 | +0.0% | +1.1% | +3.3% | +4.1% | +6.5% | +5.1% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $183.65 | $187.00 | +1.8% | +2.9% | +4.2% | +6.8% | +8.0% | +10.3% |
| Dec 10 | RBC Capital | Maintains | Outperform → Outperform | — | $185.83 | $187.77 | +1.0% | -1.0% | -1.5% | +2.0% | +3.8% | +3.7% |
| Dec 10 | Stifel | Maintains | Buy → Buy | — | $185.83 | $187.77 | +1.0% | -1.0% | -1.5% | +2.0% | +3.8% | +3.7% |
| Nov 10 | RBC Capital | Maintains | Outperform → Outperform | — | $202.48 | $204.44 | +1.0% | +3.4% | +3.1% | +1.5% | -0.6% | -0.8% |
| Nov 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $208.22 | $205.45 | -1.3% | -2.8% | +0.5% | +0.2% | -1.3% | -3.3% |
Recent Filings
8-K · 1.02
!! High
Ligand Pharmaceuticals Incorporated -- 8-K 1.02: Material Agreement Terminated
The TR-Beta Program license termination with Valley Blvd effective May 4, 2026 removes a development partnership, though the filing doesn't specify whether this was mutual, breach-based, or regulatory-driven—investors should clarify the reason's impact on the company's pipeline.
Apr 30
8-K
XOMA ROYALTY CORP - XOMA 8 5/8 PERP -- 8-K Filing
Legendarily XOMA Royalty shareholders will receive cash and contingent value rights tied to RemainCo LLC interests in the merger, providing potential future payments beyond immediate consideration.
Apr 27
8-K
LIGAND PHARMA-GENERAL CVR -- 8-K Filing
Ligand Pharmaceuticals shareholders will receive cash plus contingent value rights tied to RemainCo LLC's future performance under the merger agreement's CVR structure.
Apr 27
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The CFO's departure effective April 10, 2026 signals potential financial uncertainty or strategic shifts at Ligand Pharmaceuticals and Path Therapeutics, requiring investors to monitor interim leadership decisions and financial guidance updates closely.
Apr 10
8-K
Unknown — 8-K Filing
Repricing underwater stock options for 2.4 million shares avoids immediate dilution but signals weak equity performance and may frustrate existing shareholders who see compensation costs shifted rather than eliminated.
Apr 3
8-K
Ligand Pharmaceuticals Inc. -- 8-K Filing
Ligand Pharmaceuticals delivered 48% royalty revenue growth in 2025 while maintaining 2026 guidance of $245-$285 million in revenues and $8.00-$9.00 adjusted EPS, signaling confidence in sustained profitability.
Feb 26
Data updated apr 25, 2026 7:03pm
· Source: massive.com